MARKET

MNPR

MNPR

Monopar Therapeutics Inc
NASDAQ
114.90
+0.44
+0.38%
Pre Market: 114.95 +0.05 +0.04% 05:03 08/13 EDT
OPEN
115.19
PREV CLOSE
114.46
HIGH
117.46
LOW
110.51
VOLUME
250
TURNOVER
0
52 WEEK HIGH
124.82
52 WEEK LOW
29.18
MARKET CAP
769.72M
P/E (TTM)
-60.5183
1D
5D
1M
3M
1Y
5Y
1D
Buy Rating Reiterated on Monopar as ALXN-1840 Advances in Wilson Disease; $125 Price Target Maintained
TipRanks · 1h ago
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), Achieve Life Sciences (ACHV) and OptimizeRx (OPRX)
TipRanks · 2h ago
Barclays Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
TipRanks · 3h ago
Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile
TipRanks · 14h ago
Analysts Are Bullish on Top Healthcare Stocks: Monopar Therapeutics Inc (MNPR), AbSci (ABSI)
TipRanks · 15h ago
Monopar Therapeutics Price Target Raised to $133.00/Share From $117.00 by BTIG
Dow Jones · 15h ago
Monopar Therapeutics Is Maintained at Buy by BTIG
Dow Jones · 15h ago
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133
Benzinga · 15h ago
More
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Webull offers Monopar Therapeutics Inc stock information, including NASDAQ: MNPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNPR stock methods without spending real money on the virtual paper trading platform.